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Abstract
The prevalence of obesity has been increasing worldwide. Chemerin is a recently discovered adipokine secreted by the enlarged adipose tissue
with diverse biological effects that are not well detailed yet. This study aimed to elucidate the potential role of chemerin in oxidative stress and
inflammation that are characteristics for excess weight and may eventually lead to insulin resistance and atherosclerotic complications. We also
analysed the associations between chemerin and classical adipokines, namely leptin and adiponectin. Therefore, we investigated non-diabetic
obese patients without manifest cardiovascular disease and compared their data to healthy lean individuals. Chemerin correlated positively with
markers of oxidative stress and inflammation, while it showed a negative correlation with the measure of antioxidant status, characterized by
the HDL-linked paraoxonase-1 enzyme. Chemerin also correlated positively with leptin and negatively with adiponectin respectively. In our study
population, oxidized low-density lipoprotein and high-sensitivity C-reactive protein were found to be the strongest predictors of chemerin level.
We conclude that chemerin may contribute to chronic inflammation and increased oxidative stress in obese individuals, even in the absence of
manifest insulin resistance.
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Introduction
Obesity and overweight represent major health burdens worldwide.
Excess weight is an established cardiovascular risk factor and body
mass index (BMI) correlates positively with cardiovascular mortality
[1]. White adipose tissue, especially in the visceral compartment, is
recently considered as not a simple energy depository tissue, but also
as an active endocrine organ releasing a variety of biologically active
substances termed adipokines. Generally, adipokines are known to
play key roles in the regulation of glucose/lipid metabolism, insulin
sensitivity and inflammation. Based upon the complex interplay
between adipokines, obesity is also characterized by a chronic low-
grade inflammation with permanently increased oxidative stress [2].
The imbalance between oxidative stress and antioxidant defence also
triggers insulin resistance and results in enhanced atherosclerosis
[3]. Oxidative stress is also a hallmark of obesity-related dyslipida-
emia leading to cardiovascular diseases by decreasing aortic flow and
left ventricular function, while increasing the extent of myocardial
necrosis under experimental settings [4].
Chemerin, named also as tazarotene-induced gene protein 2 or
retinoic acid receptor responder protein 2 (RARRES2), is a novel
adipokine with biological functions that are still not elucidated yet.
The protein and its receptor (chemokine-like receptor 1, CMKLR1 or
ChemR23) are highly expressed in the adipose tissue [5], and chem-
erin is reported to regulate adipocyte differentiation and metabolism
in an autocrine/paracrine manner [6]. Chemerin also serves as a
chemoattractant for immune cells such as macrophages, natural killer
cells and dendritic cells [7]. Its exact effect on inflammation is still
not clear, as it might serve as a pro- and anti-inflammatory protein
too [8]. Recent data show that chemerin might play a role in the
development of obesity and metabolic syndrome [5, 9]. Chemerin
may also impair glucose uptake and promote insulin resistance [10];
and its level was reported to be associated positively with BMI and the
markers of inflammation and metabolic syndrome in humans [11, 12].
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Genetic studies also indicated that chemerin might be involved in adi-
pose tissue homoeostasis with increased lipogenic activity, reporting
that aged ChemR23 knockout mice were prone to develop mild obes-
ity without major defects in adipocyte differentiation [13]. The above
mentioned conditions are also characterized by increased oxidative
stress; however, the role of chemerin in such oxidative processes still
remains unknown.
The association between chemerin and classical adipokines, such
as leptin and adiponectin has also yet to be elucidated. Leptin was
reported to induce pro-inflammatory responses and its serum levels
were shown to increase with the amount of body fat [14, 15]. In fact,
leptin was found to contribute to the development of cardiac failure in
rats with experimental myocardial infarction, possibly by increasing
intramyocardial pro-inflammatory cytokine expression [16]. In con-
trast, adiponectin levels are decreased in obesity and correlate
inversely with the risk of myocardial infarction [17]. In addition,
adiponectin promotes insulin sensitivity and the production of
anti-inflammatory cytokines [18].
Altered lipoprotein profile, generally termed as atherogenic dyslip-
idaemia, is often found in obese individuals. Oxidation of low-density
lipoprotein (LDL) plays a key role in atherosclerosis [19], eventually
leading to the development of various cardiovascular diseases. Oxi-
dized LDL (ox-LDL) initiates monocyte/macrophage and endothelial
activation, smooth muscle cell proliferation and formation of foam
cells and fatty streaks [20]. Besides triggering inflammation, ox-LDL
is considered to be a useful marker for cardiovascular diseases, as lit-
erature data indicate that plasma ox-LDL level is significantly elevated
in such patients [3,21]. Indeed, levels of ox-LDL were found to corre-
late positively with the severity of acute coronary syndrome and more
severe atherosclerotic lesions contained a significantly increased
number of ox-LDL-positive macrophages [22], indicating the impor-
tance of ox-LDL in the latter stages of the atherosclerotic process
too.
Activation of the natural antioxidant defence mechanisms may
slow down the progression of atherosclerosis. In fact, enhancing anti-
oxidant capacity exhibited cardioprotective effects and was shown to
be effective in reducing atherosclerotic plaque formation in rodents
[23, 24]. Human paraoxonases are a group of enzymes encoded on
chromosome 7 that mediate the hydrolysis of organophosphates.
Paraoxonase (PON)1 is a HDL-linked enzyme with established antioxi-
dant properties that protects LDL and HDL from oxidative modifica-
tion [25–27]. PON2 is expressed ubiquitously and may also act as an
antioxidant [28], while HDL-bound PON3 has recently been described
to possess putative antioxidant effects [29]. PON1 is the most exten-
sively described member of this gene family with several different
enzyme activities, such as esterase, peroxidase and lactonase activi-
ties respectively [30]. Of note, PON1 arylesterase activity was
reported to correlate inversely with the risk of major adverse cardio-
vascular events [31]. As it is reviewed elsewhere, PON1 status is
reported to be reduced in several human diseases involving enhanced
oxidative stress, such as diabetes mellitus, hyperlipidaemia, ischae-
mic heart disease and chronic liver failure [32, 33]. Indeed, our previ-
ous data indicated that PON1 activity associated negatively with
markers of metabolic syndrome [34]. We also reported that PON1
activities were decreased in obese children and PON1 arylesterase
activity showed variable correlations with adipokine levels [35].
Variations of PON1 activities are mainly related to a common
polymorphism (Q192R) in its coding region [36]. This Gln192Arg
polymorphism yields three PON1 phenotypes with different enzymatic
activities: AA (low activity), AB (intermediate activity) and BB (high
activity) respectively. Q192R polymorphism was also shown to be
associated with an increased risk for development of obesity in
humans [37].
It should also be noted that a significant proportion of obese indi-
viduals are considered non-diabetic with normal insulin sensitivity.
In a recent study, metabolically healthy obese individuals were
reported to have lower risk of mortality and cardiovascular disease
compared to metabolically unhealthy insulin resistant counterparts
[38]; however, obese individuals still possess a significant risk of type
2 diabetes mellitus [39]. This suggests that mechanisms other than
simple caloric imbalance, such as oxidative stress, antioxidant status,
chronic inflammation and adipokine interplay might determine the
clinical outcome in obese individuals.
To our knowledge, there is no data about the association between
the levels of chemerin and ox-LDL, especially in non-diabetic obese
(NDO) individuals. Literature about correlation of chemerin levels and
paraoxonase-1 status is also lacking in these individuals. Therefore,
we aimed to investigate the above mentioned variables in NDO
patients and compared their data to non-diabetic lean individuals. We
also intended to clarify the possible associations between chemerin
levels and various markers of obesity, including lipid profile, high-
sensitivity C-reactive protein (hsCRP) and classical adipokines such
as leptin and adiponectin in these patients.
Patients and methods
Study population
The study was carried out in accordance with the Declaration of Hel-
sinki of World Medical Association and was previously approved by the
local and regional ethics committees. All investigated patients gave
their written informed consent to participate in the study. We enrolled
50 consecutive NDO patients that were referred to our obesity outpa-
tient clinic at Department of Internal Medicine, University of Debrecen
Medical and Health Center, Debrecen, Hungary; and compared their
data to 38 non-diabetic non-obese control participants matched in age
and gender, that were recruited from our department. Patients with
active liver or endocrine disease (including any type of diabetes mell-
itus), cardiovascular disease, renal impairment, malignancy, alcohol or
drug dependence were excluded. The study population was also limited
to non-smoker, non-pregnant individuals free of clinically significant
infectious diseases. Neither obese patients nor non-obese controls were
taking lipid lowering, hypoglycaemic, anti-inflammatory, antithrombotic
medications or dietary supplements. None of the studied individuals
were receiving antihypertensive treatment with the exception of 10
NDO patients, who were on diuretics (indapamide) because of mild
hypertension. BMI was calculated as a ratio of the weight to the square
of the height in SI measurements (kg/m2) and obesity was defined as
BMI ≥ 30 kg/m2.
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Biochemical assays
Venous blood samples were taken after an overnight fast and sera were
prepared immediately. Routine laboratory analyses [hsCRP, fructosa-
mine, triglyceride, total cholesterol, HDL-cholesterol (HDL-C), LDL-
cholesterol (LDL-C), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo
B), lipoprotein (a) [Lp(a)], haemoglobin A1C (HbA1C) and insulin levels]
were performed from fresh sera with Cobas c501 autoanalyzer (Roche
Ltd., Mannheim, Germany) in the Department of Laboratory Medicine of
our university. Reagents were purchased from the same vendor and the
tests were performed according to the recommendation of the manufac-
turer. To confirm non-diabetic status in the studied individuals, we
applied a routine 75-g oral glucose tolerance test (OGTT) that was per-
formed after an overnight fast, using capillary glucose measurements in
our laboratory. Homoeostasis model assessment for insulin resistance
(HOMA-IR) was calculated as described elsewhere [40].
Ox-LDL assay
Serum concentrations of ox-LDL were detected by a commercially
available solid phase two-site enzyme immunoassay kit (Mercodia AB,
Uppsala, Sweden). Measurements of the oxidized LDL levels in the sera
were performed according to the recommendations of the manufacturer.
The intra- and inter-assay coefficients of variations were 5.5–7.3% and
4.0–6.2%, respectively, and the sensitivity was <1 mU/l.
Paraoxonase-1 measurements
Paraoxonase-1 paraoxonase activity was analysed by a kinetic, semi-
automated method. Briefly, we used paraoxon (O,O-diethyl-O-p-nitrophe-
nyl-phosphate, Sigma, Hungary) as a substrate, and the generation of
4-nitrophenol was measured on a microtiter plate (Greiner Bio-One
GmbH, Frickenhausen, Germany). Serum of 15 ll was mixed with 285 ll
Tris-HCl buffer (100 mmol/l, pH = 8.0) containing 2 mmol/l CaCl2 and
5.5 mmol/l paraoxon. The absorbance was monitored at 405 nm (25°C),
in every minute for 6 min. by a Beckman Coulter DTX880 Plate Reader
(Beckman Coulter, Brea, CA, USA) equipped with a multimode detector.
Enzyme activity was calculated using the molar extinction coefficient
17,600 M/cm. Paraoxonase activity is expressed as units per litre of
serum, where 1 unit equals 1 lmol of substrate hydrolysed per minute.
Paraoxonase-1 arylesterase activity was assayed containing 1 mM
phenylacetate substrate (Sigma-Aldrich, Budapest, Hungary) in 20 mM
Tris-HCl, pH = 8.0. The reaction was started by adding the serum and
the absorbance was monitored at 270 nm. Blanks were included to cor-
rect for the spontaneous hydrolysis of phenylacetate. Enzyme activity
was calculated using the molar extinction coefficient 1310 M/cm. Ary-
lesterase activity is expressed in U/l; 1 U is defined as 1 lmol pheny-
lacetate hydrolysed per minute.
Adipokine measurements
Serum concentrations of leptin, adiponectin and chemerin were mea-
sured by a commercially available ELISA kits (R&D Systems Europe
Ltd., Abington, UK for leptin and adiponectin determinations; USCN Life
Science Inc., Wuhan, China, for chemerin measurements). The intra-
and inter-assay coefficients of variations were 3.0–3.3% and 3.5–5.4%
(leptin), 2.5–4.7% and 5.8–6.9% (adiponectin), <10% and <12%
(chemerin) respectively. Measurements of the adipokine levels in sera
were performed according to the recommendations of the manufactur-
ers.
Statistical analysis
Statistical analysis was performed by SASTM for WindowsTM 8.2 com-
puter software (SAS Institute Inc., Cary, NC, USA). Normality of distri-
bution was tested by Kolmogorov–Smirnov test. Data are expressed as
means  SD in parameters with normal distribution; and as median
(lower/upper quartile) in case of non-normal distribution. Comparisons
between groups (NDO patients versus healthy controls) were analysed
by Student’s unpaired t-tests in parameters showing normal distribution
and Mann–Whitney U-tests were performed to compare parameters with
non-normal distribution. Correlations between continuous variables were
assessed by calculation of linear regression using Pearson’s test. Multi-
ple regression analysis (backward-stepwise method) was performed to
determine variables best predicted chemerin levels. P < 0.05 was con-
sidered statistically significant.
Results
The characteristics of the study participants are shown at Table 1. As
expected, classical adipokines such as leptin and adiponectin showed
opposite changes in their levels: leptin was significantly increased in
NDO patients, while adiponectin was measured to be significantly
decreased in these patients compared to control individuals. In line
with leptin, chemerin was also found to be elevated in NDO patients,
together with significantly increased hsCRP levels. The other routinely
measured metabolic parameters were in the physiological range,
however, triglyceride, HDL-C, Apo A1 and Lp(a) concentrations were
significantly altered in the NDO group. In our study patients, normal
insulin sensitivity was confirmed by several assays, as OGTT, HbA1C,
fasting insulin levels and HOMA-IR were normal in both groups.
Ox-LDL level was significantly increased in the NDO individuals, while
PON1 paraoxonase and arylesterase activities did not show significant
differences across the groups.
Ox-LDL demonstrated a significant positive correlation with
chemerin (r = 0.401, P = 0.001), and a significant negative correla-
tion with adiponectin (r = 0.366, P = 0.004). The correlation was
non-significant between ox-LDL and leptin (r = 0.138, P = 0.346).
We also detected significant positive correlations between concentra-
tions of chemerin and LDL-C (r = 0.284, P = 0.008), and between
concentrations of chemerin and Apo B (r = 0.349, P = 0.001)
respectively; while significant negative correlations were found
between levels of chemerin and HDL-C (r = 0.296, P = 0.0057),
and between levels of chemerin and Apo A1 (r = 0.237,
P = 0.0298) respectively.
We also evaluated the PON1 phenotype distribution and the allelic
frequencies that are depicted on Table 2. Allelic frequencies followed
the Hardy–Weinberg equilibrium and no significant differences were
found between the studied groups.
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Although PON1 paraoxonase activity was not found to be associ-
ated with chemerin level (r = 0.133, P = 0.357), we detected a sig-
nificant negative correlation between PON1 arylesterase activity and
chemerin concentration (r = 0.218, P = 0.045) as it is shown on
Figure 1. The arylesterase activity of PON1 characterizes the antioxi-
dant capacity and the quantity of the enzyme bound to HDL. The neg-
ative correlation found in the whole study population persisted and
remained significant when analysing the obese patients only
(r = 0.316, P = 0.029) and we found PON1 arylesterase activity to
be unrelated to chemerin level in healthy controls (r = 0.022,
P = 0.899).
Body mass index correlated positively with leptin (r = 0.760,
P < 0.0001) and negatively with adiponectin levels (r = 0.401,
P = 0.0001). Body mass index also showed a significant positive cor-
relation with chemerin levels (r = 0.546, P < 0.0001). We also found
a significant positive correlation between the levels of hsCRP and
chemerin (r = 0.610, P < 0.0001). As previous data were confound-
ing, we also determined the associations between chemerin and for-
merly discovered adipokines. Chemerin might either act as a pro- or
anti-inflammatory molecule, while leptin and adiponectin have oppos-
ing effect on inflammation and cardiac health. Assessing the correla-
tions between chemerin, as a novel adipokine and the formerly
discovered classical adipokines, we found a significant positive corre-
lation between concentrations of leptin and chemerin (r = 0.448,
P = 0.00001) as it is demonstrated on Figure 2. Also, a significant
negative correlation was detected between adiponectin and chemerin
levels (r = 0.243, P = 0.022).
To test whether the associations detected in the univariate analy-
ses were independent of anthropometric and other laboratory param-
eters, we carried out multiple regression analysis with chemerin as
the dependent variable. The model included age, BMI, hsCRP, HDL-C,
leptin, adiponectin, PON arylesterase and ox-LDL. As it is shown on
Table 3, chemerin turned out to be best predicted by ox-LDL and
hsCRP. There were also tendencies for significance in correlations
with age and PON1 arylesterase activity; however, these associations
did not reach the level of significance.
Table 1 Anthropometric and selected laboratory parameters of the
study population
Variables
NDO
(n = 50)
Control
(n = 38)
P
Gender
(female/male)
43/7 33/5
Age (years) 44.2  13.5 42.3  11.4 n.s.
BMI (kg/m2) 41.96  8.63 24.05  3.21 <0.001
Leptin (ng/ml) 69.09  44.19 15.87  12.11 <0.001
Adiponectin
(lg/ml)
6.24  3.30 10.11  5.94 <0.001
Chemerin
(ng/ml)
590.08  90.29 404.99  127.07 <0.001
hsCRP (mg/l) 8.24 (3.2/13.09) 0.85 (0.5/1.38) <0.001
Fructosamine
(lmol/l)
225.32  27.95 233.90  15.76 n.s.
Triglyceride
(mmol/l)
1.4 (1.1/2.0) 0.9 (0.7/1.6) <0.01
Total
cholesterol
(mmol/l)
5.04  0.83 5.06  1.03 n.s.
HDL-C (mmol/l) 1.36  0.33 1.72  0.47 <0.001
LDL-C (mmol/l) 3.17  0.74 2.93  0.98 n.s.
Apo A1 (g/l) 1.48  0.24 1.66  0.39 <0.01
Apo B (g/l) 0.86  0.20 0.78  0.26 n.s
Lp(a) (mg/l) 248 (120/586) 112 (80/300) <0.01
Glucose –
OGTT 0 min.
4.90  0.75 4.41  0.57 <0.01
Glucose –
OGTT 120 min.
7.00  2.01 6.54  1.13 n.s.
HbA1C (%) 5.81  0.57 5.90  0.63 n.s.
Insulin (mU/l) 17.14  9.91 14.26  6.02 n.s.
HOMA-IR 3.2 (2.2/5.1) 2.4 (1.3/3.3) n.s.
Ox-LDL (U/l) 46.8  9.94 39.7  10.40 <0.001
PON1
paraoxonase
activity (U/l)
82.0
(45.1/149.5)
79.7
(40.0/200.0)
n.s.
PON1
arylesterase
activity (U/l)
113.95  24.90 129.19  27.01 n.s.
Data are presented as mean  SD or as median (lower/upper quar-
tile). p: NDO patients versus control individuals.
Table 2 Paraoxonase-1 phenotype distribution and allelic
frequencies
NDO (n = 50) Control (n = 38)
n (%) n (%)
AA 45 (90) 31 (82)
AB 5 (10) 7 (18)
BB 0 (0) 0 (0)
A 95 (95) 69 (91)
B 5 (5) 7 (9)
AA, AB, BB: paraoxonase-1 phenotype distribution representing differ-
ent enzymatic activities (AA phenotype: low activity; AB phenotype:
intermediate activity; BB phenotype: high activity). A: allele A; B: allele
B.
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Discussion
Recent evidence demonstrates the role of chemerin in the devel-
opment of obesity-related insulin resistance, while dyslipidaemia
and inflammation are known to enhance atherosclerosis [10, 41];
however, data are conflicting. In our study, despite unaltered
insulin sensitivity, we found significantly increased chemerin and
leptin levels and significantly decreased adiponectin concentra-
tions in obese patients. Although lipid parameters were in the
normal range in our study, the adipokine pattern of NDO patients
was paralleled by atherogenic dyslipidaemia, compared to lean
patients. Significantly increased hsCRP levels confirmed the
chronic low-grade inflammation in NDO patients that is also char-
acteristic for obesity [42]. Our results indicate the early presence
of unfavourable pro-atherogenic processes in NDO patients
that might eventually lead to cardiovascular disease or insulin
resistance.
The adipokine profile of our patients is in agreement with previous
data suggesting that circulating chemerin level is increased in obesity
and might play a key role in obesity-related disorders [8]. Indeed,
chemerin concentration was found to be increased in nascent meta-
bolic syndrome [9] and it also showed significant correlations with
altered lipid parameters [43]. We also detected significant positive
correlations between the concentrations of pro-atherogenic lipid
parameters (LDL-C, Apo B) and chemerin; while significant negative
correlations were found between the levels of anti-atherogenic lipid
measures (HDL-C, Apo A1) and chemerin respectively. Our findings
also imply that chemerin might play an important role in athero-
sclerosis.
In congruence with dyslipidaemia, ox-LDL was significantly
elevated in the NDO individuals. In turn, PON1 paraoxonase and
arylesterase activities did not show significant differences across
the groups, indicating the early imbalance between pro-oxidant
mechanisms and antioxidant defence. Although obesity and dyslip-
idaemia are characterized by increased oxidative stress, data are
extremely scarce and confounding about the in vivo associations
of chemerin and oxidative status. Ox-LDL is a key lipid peroxida-
tion product generated in the early stages of atherosclerosis [19].
Indeed, we found increased oxidized LDL levels in NDO patients,
which demonstrated a significant positive correlation with chemer-
in and a significant negative correlation with adiponectin. These
novel data support the assumption that chemerin might be
involved in increased oxidative stress that is observed often in
these patients.
As dyslipidaemia, increased oxidative stress and unfavourable
adipokine profile was found in the NDO patients together with
absence of altered paraoxonase activities, we evaluated the PON1
phenotype distribution and the allelic frequencies. Our findings
were in accordance with the results of our and other research
groups [44, 45]. No significant differences were found between
the studied groups indicating the same prevalence of PON1
Q192R polymorphism in our patients. PON1 arylesterase activity
correlated negatively with chemerin concentration when analysing
the whole study population or the NDO individuals, which indi-
cates the impact of obesity on antioxidant capacity even in the
absence of manifest insulin resistance or cardiovascular compli-
cations. To the best our knowledge, this is the first report about
A
B
C
Fig. 1 Association of PON1 arylesterase activity with chemerin in all
studied individuals (A), in non-diabetic obese patients (B) and in lean
controls (C).
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the inverse relationship between chemerin and the HDL-linked
paraoxonase. This, together with our novel results regarding
chemerin and its association with ox-LDL, may support the
impact of chemerin on oxidant/antioxidant status in obesity.
PON1 arylesterase activity is responsible for the hydrolysis of
phospholipid and cholesterol ester hydroperoxides and it is pro-
portional to the quantity of PON1 enzyme protein linked to HDL
[46]. Ox-LDL is also known to inactivate PON1 arylesterase [47].
Despite the increased ox-LDL levels observed in the obese
patients, we found slightly, but not significantly decreased ary-
lesterase activity in these individuals. Taken into account that
PON1 is produced by the liver and chemerin also shows a high
expression in this organ of rats and humans especially in non-
alcoholic steatosis that is closely associated with obesity [5, 48],
it is tempting to speculate that chemerin might modify the
synthesis of PON1 in the hepatocytes of the obese patients.
However, further studies are needed to clarify this putative mech-
anism.
Corroborating previous data [49], BMI correlated positively with
leptin levels and negatively with adiponectin concentrations. Body
mass index also showed a significant positive correlation with chem-
erin levels. Chemerin mRNA is abundantly expressed in white adipose
tissue in humans and its receptor is mainly expressed in immune and
fat cells [5], raising the link between obesity and inflammation.
Chemerin is secreted as an 18 kDa inactive form that undergoes fur-
ther enzymatic proteolysis generating either pro-inflammatory and
chemotactic effects or anti-inflammatory signalling [50]. In our study
patients, we found a significant positive correlation between the levels
of hsCRP and chemerin, indicating the possible modulating role of
chemerin in inflammation.
Assessing the correlations between chemerin, as a novel adipoki-
ne and the formerly discovered classical adipokines, we found a sig-
nificant positive correlation between concentrations of leptin and
chemerin. Also, a significant negative correlation was detected
between adiponectin and chemerin levels. Although previous studies
found no association between chemerin and adiponectin in patients
with various BMI [12, 51], here we report a negative correlation of
chemerin to adiponectin, which, together with the positive association
with leptin, may further support the potential role of chemerin in the
development of obesity-related disorders. As adiponectin and leptin
are considered to have opposing effects on inflammation in obesity
[52], these findings rather indicate a pro-inflammatory role of chem-
erin in NDO patients.
Based upon our multiple regression analysis, chemerin turned
out to be best predicted by ox-LDL and hsCRP. These novel findings
also highlight the importance of chemerin in inflammation and reveal
its possible role in the regulation of oxidant/antioxidant balance. Our
data indicate that obesity, even without manifest insulin resistance,
predisposes to enhanced atherosclerosis and increased oxidative
stress, in which chemerin functions as a potential modulator of
inflammation and oxidant/antioxidant status. Our results support the
hypothesis that circulating chemerin levels are already elevated in
Table 3 Multiple regression analysis for chemerin as a dependent
variable
Variable b P
Ox-LDL 0.381 0.005
hsCRP 0.284 0.029
Age 0.230 0.068
PON1 arylesterase activity 0.230 0.075
BMI 0.175 0.302
HDL-C 0.136 0.411
Adiponectin 0.121 0.438
Leptin 0.114 0.475
A
B
Fig. 2 Association of chemerin with leptin (A) and adiponectin (B).
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NDO patients that are free of manifest insulin resistance and cardio-
vascular diseases. The early presence of low-grade inflammation and
oxidative stress modulated by chemerin predisposes to accelerated
atherogenesis in obesity. Therefore, chemerin might serve as an
early biomarker for increased cardiovascular risk in obese patients
without manifest complications and might be a useful tool for timely
intervention to prevent the development of subsequent atheroscle-
rotic complications. However, further studies are needed to clarify
the role of chemerin in the long-term cardiovascular outcome in
obese patients.
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